356 related articles for article (PubMed ID: 29089755)
1. Cost-effectiveness of the Aerobika* oscillating positive expiratory pressure device in the management of COPD exacerbations.
Khoudigian-Sinani S; Kowal S; Suggett JA; Coppolo DP
Int J Chron Obstruct Pulmon Dis; 2017; 12():3065-3073. PubMed ID: 29089755
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada.
Thanh NX; Jacobs P; Suggett J; McIvor A; Kaplan A
Can Respir J; 2019; 2019():9176504. PubMed ID: 30774739
[TBL] [Abstract][Full Text] [Related]
3. Impact of Oscillating Positive Expiratory Pressure Device Use on Post-Discharge Hospitalizations: A Retrospective Cohort Study Comparing Patients with COPD or Chronic Bronchitis Using the Aerobika
Tse J; Wada K; Wang Y; Coppolo D; Kushnarev V; Suggett J
Int J Chron Obstruct Pulmon Dis; 2020; 15():2527-2538. PubMed ID: 33116469
[TBL] [Abstract][Full Text] [Related]
4. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of physical activity in the management of COPD patients in the UK.
Ramos M; Lamotte M; Gerlier L; Svangren P; Miquel-Cases A; Haughney J
Int J Chron Obstruct Pulmon Dis; 2019; 14():227-239. PubMed ID: 30697043
[TBL] [Abstract][Full Text] [Related]
6. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
[TBL] [Abstract][Full Text] [Related]
7. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy.
Palli SR; Zhou S; Shaikh A; Willey VJ
J Manag Care Spec Pharm; 2021 May; 27(5):625-637. PubMed ID: 33779246
[No Abstract] [Full Text] [Related]
8. A Real-World Evidence Study Assessing the Impact of Adding the Aerobika Oscillating Positive Expiratory Pressure Device to Standard of Care Upon Healthcare Resource Utilization and Costs in Post-Operative Patients.
Burudpakdee C; Near AM; Huang H; Coppolo D; Kushnarev V; Suggett J
Pulm Ther; 2018 Jun; 4(1):87-101. PubMed ID: 32026246
[TBL] [Abstract][Full Text] [Related]
9. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
[TBL] [Abstract][Full Text] [Related]
10. A new method for examining the cost savings of reducing COPD exacerbations.
Mapel DW; Schum M; Lydick E; Marton JP
Pharmacoeconomics; 2010; 28(9):733-49. PubMed ID: 20799755
[TBL] [Abstract][Full Text] [Related]
11. Impact of Aerobika
Sahardin SN; Jailaini MFM; Abeed NNN; Ban AY; Hau NB; Azmel AA; Shah SA; Hamid MFA
Front Med (Lausanne); 2023; 10():1202380. PubMed ID: 37332765
[TBL] [Abstract][Full Text] [Related]
12. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
Moll K; Sun SX; Ellis JJ; Howe A; Amin A
Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
[TBL] [Abstract][Full Text] [Related]
13. COPD management costs according to the frequency of COPD exacerbations in UK primary care.
Punekar YS; Shukla A; Müllerova H
Int J Chron Obstruct Pulmon Dis; 2014; 9():65-73. PubMed ID: 24426781
[TBL] [Abstract][Full Text] [Related]
14. Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population.
Coutinho AD; Lokhandwala T; Boggs RL; Dalal AA; Landsman-Blumberg PB; Priest J; Stempel DA
Int J Chron Obstruct Pulmon Dis; 2016; 11():1223-31. PubMed ID: 27354781
[TBL] [Abstract][Full Text] [Related]
15. Effect of tele health care on exacerbations and hospital admissions in patients with chronic obstructive pulmonary disease: a randomized clinical trial.
Ringbæk T; Green A; Laursen LC; Frausing E; Brøndum E; Ulrik CS
Int J Chron Obstruct Pulmon Dis; 2015; 10():1801-8. PubMed ID: 26366072
[TBL] [Abstract][Full Text] [Related]
16. The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece.
Souliotis K; Kousoulakou H; Hillas G; Tzanakis N; Toumbis M; Vassilakopoulos T
Int J Chron Obstruct Pulmon Dis; 2017; 12():1395-1400. PubMed ID: 28546747
[TBL] [Abstract][Full Text] [Related]
17. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
Jahnz-Rózyk K; Targowski T; From S
Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
[TBL] [Abstract][Full Text] [Related]
19. Translating Pharmacometrics to a Pharmacoeconomic Model of COPD.
Slejko JF; Willke RJ; Ribbing J; Milligan P
Value Health; 2016 Dec; 19(8):1026-1032. PubMed ID: 27987629
[TBL] [Abstract][Full Text] [Related]
20. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
